Výsledky vyhledávání - "Piotr Krzeski"

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis

Autor: Sanja Kolaček, Preston M. Dunnmon, Harland S. Winter, Eduardo Ibarguen-Secchia, Bankole Osuntokun, Melvin B. Heyman, Manoj Shah, Maciej Kaczmarski, J Antonio Quiros, Bruce R. Yacyshyn, Jaroslaw Kierkus, Barbara Iwańczak, Piotr Krzeski

Publikováno v: Journal of Pediatric Gastroenterology and Nutrition

Objective: The aim of the study was to assess the safety and efficacy of high- and low-dose oral, delayed-release mesalamine in a randomized, double-blind, active control study of children with mild-to-moderately active ulcerative colitis. Methods: P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::395d52da545dc78169d68aa4e80efe0f
https://doi.org/10.1097/mpg.0000000000000530

Zobrazit plný text záznamu

Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity

Autor: Christian A. Bernhardt, Bruce E. Sands, Simon Travis, Maria T. Abreu, Piotr Krzeski, Patrick Schnell, William J. Sandborn, Stephen B. Hanauer, Walter Reinisch, Douglas G. Altman, Brian G. Feagan, Jean Yves Mary, Bruce R. Yacyshyn, Gary R. Lichtenstein, Philippe Marteau, Jean-Frederic Colombel, Dan Schnell

Publikováno v: Gastroenterology. 145:987-995

Background & Aims We studied the reliability of the previously described Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and validated it with an independent cohort of investigators. Methods We created a new library of 57 videos of flexible s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee57287b7bcc6cca0460b8fe76559ae5
https://doi.org/10.1053/j.gastro.2013.07.024

Zobrazit plný text záznamu

Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction

Autor: Henry E. Kim, Jose Brum, Miguel A. Quinones, Wael A. Jaber, Witold Rużyłło, Lisa Cusmano, Robert A. Lyon, Diana Sydlowski, Mario J. Garcia, W. Douglas Weaver, Paul W. Armstrong, Michael P. Hudson, Piotr Krzeski, Pierre Theroux

Publikováno v: Journal of the American College of Cardiology. 48:15-20

Objectives We sought to determine whether matrix metalloproteinase (MMP) inhibitor, PG-116800, reduced left ventricular (LV) remodeling after myocardial infarction (MI). Background PG-116800 is an oral MMP inhibitor with significant antiremodeling ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33bc40e138369bf7fedb3b74760bca4b
https://doi.org/10.1016/j.jacc.2006.02.055

Zobrazit plný text záznamu

Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?

Autor: Bohdan Milewski, Andrzej Habior, Włodzimierz Zych, Eugeniusz Butruk, Piotr Krzeski, Ewa Kraszewska

Publikováno v: Hepatology. 30:865-869

From the many prognostic models for primary biliary cirrhosis (PBC) patients based on Cox's regression analysis, the Mayo model has gained the most popularity and was successfully validated in some centers. The aim of our study was to validate the Ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d58ba04247fa02706276019c873bc77
https://doi.org/10.1002/hep.510300415

Zobrazit plný text záznamu

Severity of primary sclerosing cholangitis and ulcerative colitis: does liver transplantation protect against colectomy?

Autor: Piotr Krzeski

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 10(12)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f910ca063b6601f59cd12abc08e7b4f5
https://pubmed.ncbi.nlm.nih.gov/22245961

Zobrazit plný text záznamu

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

Autor: Jaroslaw Regula, Chyon Yeh, Elena Belousova, Milan Lukas, Piotr Krzeski, William J. Sandborn, Stephen B. Hanauer, Brian G. Feagan, Christi A. Messer, Bruce R. Yacyshyn, Njegica Jojic

Publikováno v: Gastroenterology. 137(6)

Background and Aims It is not clear what induction dose of mesalamine is optimal for treating patients with mildly and moderately active ulcerative colitis (UC). This study was conducted to determine the efficacy and safety of mesalamine 4.8 g/day co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9544ae550e3aa243d335bb0bd0d6c48
https://pubmed.ncbi.nlm.nih.gov/19879213

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání